Welcome to Oncology Newswatch's case report exploration. This interactive case report will engage your experience and knowledge about details of a given case. Along the way, we will provide details and at the end, we will share the patient's outcome.

Conferences

Drs Morton Coleman and Ruben Niesvizky summarize the key take-home points presented on multiple myeloma during Lymphoma & Myeloma 2016: An International Congress on Hematologic Malignancies, and examine their clinical implications.

Features

Welcome to Oncology Newswatch's case report exploration. This interactive case report will engage your experience and knowledge about details of a given case. Along the way, we will provide details and at the end, we will share the patient's outcome.

News

The National Comprehensive Cancer Network treatment guidelines for multiple myeloma still promote the use of supportive care as a critical component of care.
Patients with multiple myeloma may not be receiving optimal therapy for bone disease.
A recent study found over 18% of patients with relapsed or refractory multiple myeloma treated with a proteasome inhibitor were faced with cardiovascular adverse events.
The addition of daratumumab to a conventional regimen is associated with a 2-fold increase in PFS in patients with newly diagnosed multiple myeloma who are ineligible for transplant.
Subscribe to Multiple Myeloma